Mast Therapeutics Inc (NYSEMKT:MSTX) hit new 52-week high before its Chief Executive Officer, Brian M. Culley’s presentation at the OneMedForum Emerging Company Finance Conference on Tuesday, January 14th, 2014 at 2:10 p.m. Pacific time at The Westin Hotel in San Francisco. Mast Therapeutics Inc (NYSEMKT:MSTX) stock opened at $0.96 in last session, and closed at $0.800, while the day range of stock is $0.75 – $1.03. The stock showed a positive weekly performance of 42.86%.
Novavax, Inc. (NASDAQ:NVAX) shares surged 6.37% Monday as the company declared a number of promotions within its clinical operations group in preparation for expanded clinical trial activities in 2014 and 2015. Novavax, Inc. (NASDAQ:NVAX) stock opened at $5.65, in last session and closed at $6.12, by gaining 11.07%. The 52 week range of the stock is $1.68 – $6.19. Company’s market capitalization is $1.28 billion.
Peregrine Pharmaceuticals (NASDAQ:PPHM) grew 9.54% on CNBC Comments. Last week, the U.S. Food and Drug Administration (FDA) gave the company Fast Track designation for its lead investigational immunotherapy bavituximab for the potential treatment of second-line non-small cell lung cancer (NSCLC). Peregrine Pharmaceuticals (NASDAQ:PPHM) stock decreased -3.37% and finished the last session at $1.72. The EPS of the stock remained -0.20. Company’s market capitalization is $275.76 billion.
Shares of Cell Therapeutics Inc (NASDAQ:CTIC) rose after the company said it ended a licensing agreement with Novartis that covered two cancer drugs. Cell Therapeutics Inc (NASDAQ:CTIC) stock opened the session at $2.99, and closed the session at $3.05. The 52 week range of the stock remained $0.97 – $3.06 and the day range was $2.90 – $3.06.
Leave a Reply